Merck’s Phase 3 KEYNOTE-C93 trial met its primary endpoint for the treatment of endometrial cancer. Keytruda monotherapy significantly improved progression-free survival compared to standard chemotherapy.
The study evaluated patients with advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer in a first-line setting. This marks the first Phase 3 trial where an anti-PD-1 therapy alone demonstrated superior results over chemotherapy for this specific patient group.
While data for the overall survival endpoint is not yet mature, Merck reported a positive trend in the results. The company plans to submit these findings to regulatory authorities to establish a potential chemotherapy-free treatment option.